

11.06.00

**UTILITY PATENT APPLICATION TRANSMITTAL
(Small Entity)***(Only for new nonprovisional applications under 37 CFR 1.53(b))*Docket No.
ISPH-0500

Total Pages in this Submission

TO THE ASSISTANT COMMISSIONER FOR PATENTS**Box Patent Application
Washington, D.C. 20231**

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

NUCLEASE-BASED METHOD FOR DETECTING AND QUANTITATING OLIGONUCLEOTIDES

and invented by:

Yu et al.

If a **CONTINUATION APPLICATION**, check appropriate box and supply the requisite information:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____

Which is a:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____

Which is a:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____

Enclosed are:

Application Elements

1. ☒ Filing fee as calculated and transmitted as described below
2. ☒ Specification having 37 pages and including the following:
 - a. ☒ Descriptive Title of the Invention
 - b. ☐ Cross References to Related Applications *(if applicable)*
 - c. ☐ Statement Regarding Federally-sponsored Research/Development *(if applicable)*
 - d. ☐ Reference to Microfiche Appendix *(if applicable)*
 - e. ☒ Background of the Invention
 - f. ☒ Brief Summary of the Invention
 - g. ☒ Brief Description of the Drawings *(if drawings filed)*
 - h. ☒ Detailed Description
 - i. ☒ Claim(s) as Classified Below
 - j. ☒ Abstract of the Disclosure

UTILITY PATENT APPLICATION TRANSMITTAL
(Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
ISPH-0500

Total Pages in this Submission

Application Elements (Continued)

3. ☒ Drawing(s) *(when necessary as prescribed by 35 USC 113)*
a. ☐ Formal b. ☒ Informal Number of Sheets 7
4. ☒ Oath or Declaration
a. ☐ Newly executed *(original or copy)* ☒ Unexecuted
b. ☐ Copy from a prior application (37 CFR 1.63(d)) *(for continuation/divisional application only)*
c. ☒ With Power of Attorney ☐ Without Power of Attorney
d. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application,
see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5. ☐ Incorporation By Reference *(usable if Box 4b is checked)*
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under
Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby
incorporated by reference therein.
6. ☐ Computer Program in Microfiche
7. ☒ Genetic Sequence Submission *(if applicable, all must be included)*
a. ☒ Paper Copy
b. ☒ Computer Readable Copy
c. ☒ Statement Verifying Identical Paper and Computer Readable Copy

Accompanying Application Parts

8. ☐ Assignment Papers *(cover sheet & documents)*
9. ☐ 37 CFR 3.73(b) Statement *(when there is an assignee)*
10. ☐ English Translation Document *(if applicable)*
11. ☐ Information Disclosure Statement/PTO-1449 ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Acknowledgment postcard
14. ☒ Certificate of Mailing
☐ First Class ☒ Express Mail *(Specify Label No.):* EL156906487US

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
ISPH-0500

Total Pages in this Submission

Accompanying Application Parts (Continued)

15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)

16. ☐ Small Entity Statement(s) - Specify Number of Statements Submitted: _____

17. ☐ Additional Enclosures (please identify below):

Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)

18. ☐ Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

Warning

An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

UTILITY PATENT APPLICATION TRANSMITTAL
(Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
ISPH-0500

Total Pages in this Submission


Fee Calculation and Transmittal

CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	11	- 20 =	0	x \$9.00	\$0.00
Indep. Claims	1	- 3 =	0	x \$40.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
BASIC FEE					\$355.00
OTHER FEE (specify purpose) _____					\$0.00
TOTAL FILING FEE					\$355.00

- ☒ A check in the amount of **\$355.00** to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge and credit Deposit Account No. **12-1086** as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____ as filing fee.
- ☒ Credit any overpayment.
- ☒ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
- ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Dated: November 3, 2000



Signature

Jane Massey Licata
Reg. No. 32,257
Licata & Tyrrell P.C.
66 E. Main Street
Marlton, NJ 08053
Tel: 856-810-1515
Fax: 856-810-1454

CC:

ISPH-0500

CERTIFICATE OF EXPRESS MAILING



"Express Mail" Label No.EL156906487US

Date of Deposit NOVEMBER 3, 2000

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R 1.10 on the date indicated above and is addressed to the "BOX SEQUENCE", Assistant Commissioner for Patents, Washington, D.C. 20231.

- 1) Patent Application Transmittal Letter (2 copies);
- 2) Application consisting of 37 pages of Specification, including two (2) pages of Claims, and one (1) page of Abstract;
- 3) Seven (7) sheets of Informal Drawings;
- 4) Return Post Card;
- 5) Check in the amount of \$355.00;
- 6) Unexecuted Declaration and Power of Attorney;
- 7) Statement to Support Filing and Submission in Accordance with 37 C.F.R. §§1.821-1.825;
- 8) Sequence listing; and
- 9) Diskette containing computer readable copy of Sequence Listing.

JANE MASSEY LICATA
JANE MASSEY LICATA

NUCLEASE-BASED METHOD FOR DETECTING AND QUANTITATING
OLIGONUCLEOTIDES

FIELD OF THE INVENTION

5

The present invention is directed to a nuclease-based solid phase assay for detecting oligonucleotides in samples of bodily fluids and/or extracts.

10 BACKGROUND OF THE INVENTION

The detection of specific nucleic acid sequences is commonplace in the research laboratory. Southern (*J. Mol. Biol.* 1975.98:503-527) teaches detection of specific sequences among DNA fragments separated by gel electrophoresis using
15 "blotting" or transfer of the DNA fragments to a membrane, followed by hybridization of denatured DNA fragments with radioactive probes and autoradiography. This procedure has been extended to the detection of RNA molecules extracted from cells or tissues ("Northern" blotting). Further improvements
20 have involved faster and more quantitative "dot-blotting" procedures to detect DNA or RNA from tissues or cells.

Other methods are used to detect and characterize specific nucleic acid sequences and sequence changes. These methods must be able to create detectable signals from a very
25 low copy number of the sequence of interest. Nucleic acids detection methods include capillary gel electrophoresis (CGE) (U.S. Patent 5,420,265) and signal amplification technology such as the polymerase chain reaction (PCR) (U.S. Patents 4,683,195 and 4,683,202) and ligase chain reaction
30 (LCR) (Barany, *Proc. Natl. Acad. Sci.* 1991.88:189).

Recently, considerable interest has been generated in the development of synthetic antisense oligonucleotides as therapeutic agents. These antisense molecules and strategies

for their use have been reviewed by Agarwal (*Trends in Biotechnology* 1991.10:152-158) and Crooke (*Antisense Research and Applications*, Chapter 1, Basic Principles of Antisense Therapeutics, Springer-Verlag Press, New York, 1998). For an
5 antisense therapeutic to be effective, the oligonucleotide must be administered to a patient and must reach the specific nucleic acid target for which it was designed. Consequently, there is a need to be able to detect oligonucleotides in bodily fluids and extracts. In animal models, radiolabeled
10 oligonucleotides have been administered to the subject and the distribution of the oligonucleotides within the body has been assessed by extraction of the oligonucleotides followed by autoradiography (Agarwal et al. *Proc. Natl. Acad. Sci.* 1991.88:7595-7599). A common aspect of current procedures is
15 the detection of large DNA or RNA molecules (> 100bp). Due to the small size (20-30bp) of oligonucleotides used for antisense therapeutics, special problems relating to their detection exist, such as, for example, nonspecific binding or the absence of binding to probes producing false
20 negatives/positives.

Both the detection and characterization of specific nucleic acid sequences and sequence changes have been utilized to determine the presence of viral or bacterial nucleic acid sequences indicative of an infection. Further uses of such
25 approaches have allowed for the detection of the presence of variants or alleles of mammalian genes associated with disease, the identification of the source of nucleic acids found in forensic samples, as well as in paternity determinations.

30 There is a need for sensitive methods or processes for detecting administered modified oligonucleotide compounds, such as antisense therapeutics. Highly sensitive methods would be useful for determining the concentrations of modified oligonucleotide therapeutics in animal models and/or in the
35 clinic. Further uses would be to study the pharmacokinetic

properties of oligonucleotide therapeutics in animal models and/or in the clinic.

SUMMARY OF THE INVENTION

5 The present invention relates to methods for detecting oligonucleotides in bodily fluids and extracts. The methods are also useful for quantifying oligonucleotides and/or investigating the pharmacokinetics of oligonucleotides.

10 Thus, in a first aspect, the present invention features a method for screening a bodily fluid and/or extract for the presence of an oligonucleotide. Preferably, the oligonucleotide comprises one or more modifications to the backbone and/or nucleotide bases. In a preferred embodiment the sample of bodily fluid and/or extract is mammalian plasma,
15 blood or serum, and more preferably the sample is a human plasma sample. Detection of the oligonucleotide is performed by contacting the sample of bodily fluid and/or extract with a labeled probe, contacting the sample with a single strand-specific nuclease to degrade labeled, unhybridized probe and
20 detecting the binding of modified oligonucleotide to the probe.

 In one embodiment of the invention, the probe incorporates a detectable marker, for example digoxigenin, and has a nucleotide sequence which hybridizes to the
25 oligonucleotide to be detected. The probe is also configured to bind to a solid support, for example via interaction of a biotin moiety with a streptavidin coated support. Both the bound and unbound probe are allowed to bind to the solid support, followed by addition of a single-strand specific
30 nuclease, preferably nuclease S1, which degrades the unbound probe and allows the detectable marker associated with the unbound probe to be removed. Thus, only the bound probe will be detected and is directly correlated with the amount of administered oligonucleotide present. The detectable marker
35 is then detected by formation of a detectable label. For

example, detection of the oligonucleotide may be performed by binding of digoxigenin to an antidigoxigenin-alkaline phosphatase conjugate which will catalyze the formation of the detectable label, ATTOPHOS, which is detectable by 5 fluorometric methods.

In a preferred embodiment, the detectable marker is a hapten, more preferably digoxigenin, or a fluorescent chromophore such as fluorescein or rhodamine. In preferred 10 embodiments, the appropriate binding partner for the detectable marker is anti-digoxigenin antibody conjugated to alkaline phosphatase or chemiluminescent labels such as luciferase. Other detectable markers, binding partners and labels including electro-chemical indicators and/or other antibody-enzyme combinations may also be used.

15 In another preferred embodiment, the nuclease is S1 nuclease, although any single strand-specific nuclease may be used.

Monitoring the sample for the presence of the detectable label or its binding partner may be performed by apparatus 20 such as spectrophotometers, fluorometers and the like, or by visual interpretation or autoradiographic techniques.

Further aspects of the invention are described within the description of the preferred embodiments. The summary of 25 the invention described above is not limiting and other features and advantages of the invention will be apparent from the following detailed description of the invention and from the claims.

30 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic diagram showing the mechanism of the nuclease-based cutting assay of the present invention. B=binding moiety; D=detectable marker. The cross-hatched area represents a solid support coated with a compound to which the 35 binding moiety binds.

Figure 2 is a schematic diagram showing the assay method of the present invention.

Figure 3 is a graph comparing different antisense oligonucleotides. ISIS 104838: 5'-GCTGATTAGAGAGAGGTCCC-3' (SEQ ID NO:1); ISIS 2302: GCCCAAGCTGGCATCCGTCA (SEQ ID NO: 2); N-1 104838 3': ISIS 104838 metabolite shortened by one nucleotide at the 3'-end; 2302 N-1 3': ISIS 2302 metabolite shortened by one nucleotide at the 3'-end; 2302 N-1 5': 2302 shortened by one nucleotide at the 5'-end. ISIS 104838 has a 2'-O-methoxyethyl ribose at positions 1-5 and 16-20, and all internucleoside linkages are phosphorothioates.

Figure 4 is a graph comparing different modified antisense oligonucleotides which contain methoxyethyl (MOE) modifications at the 2' position of the ribose sugar. 22023=5'-TCCAGCACTTTCTTTCCGG-3' (SEQ ID NO: 3); 113715=5'-GCTCCTTCCACTGATCCTGC-3' (SEQ ID NO: 4). ISIS 22023 and ISIS 113715 have a 2'-O-methoxyethyl ribose at positions 1-5 and 16-20, and all internucleoside linkages are phosphorothioates.

Figure 5 is a graph showing the pharmacokinetic profile of ISIS 22023 following 50 mg/kg subcutaneous injection in mice. Plasma samples were analyzed at various time points using the oligonucleotide detection method of the present invention.

Figure 6 is a representative calibration curve of ISIS 104838 in human plasma from 100 pM to 200 pM using the oligonucleotide detection method of the present invention. Each calibration point was run in duplicate.

Figure 7 is a representative calibration curve of ISIS 104838 in human plasma from 1 nM to 20 nM using the oligonucleotide detection method of the present invention. Each calibration point was run in duplicate.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a highly sensitive method for detecting oligonucleotides, particularly modified

oligonucleotides, in a bodily fluid and/or extract. Current methods for detecting and or quantitating oligonucleotides such as capillary gel electrophoresis (CGE) provide increased detection of small molecules when compared to traditional
5 slab-gel electrophoresis. CGE has been used for size-based separation of biological macromolecules such as DNA restriction fragments, proteins and oligonucleotides. The methods described herein provide a 500-1000 fold increase in the sensitivity of detection of oligonucleotides in biological
10 samples when compared to methods such as CGE.

The present method can be used, for example, to detect, localize and quantify administered oligonucleotides in bodily fluids and extracts taken from patients undergoing antisense oligonucleotide therapy. Further uses for this invention are
15 for studying the pharmacokinetic properties of oligonucleotides in animal models and in humans.

The oligonucleotide detection method of the present invention, referred to herein as the "cutting assay", is summarized in Figures 1 and 2. An oligonucleotide, preferably
20 an oligonucleotide which has been administered to a subject, is detected by obtaining a sample of bodily fluid and/or extract from the subject and contacting the sample with a probe which has a sequence which is complementary to the administered oligonucleotide. The probe also comprises a
25 detectable marker and a moiety which allows binding of the probe to a solid support to which the binding partner of the moiety is bound. Solid supports include, for example, beads, culture dishes and 96-well plates. In a preferred embodiment, the detectable marker is digoxigenin which is incorporated
30 into the probe using digoxigenin-labeled UTP (D-UTP), and the moiety which allows binding of the probe to the solid support is biotin which binds to a streptavidin-coated solid support. Both the bound (probe+oligonucleotide analyte) and unbound probes bind to the solid support. A single strand-specific
35 nuclease is then added to degrade the unhybridized probe and

the solid support is washed to remove the degradation products. Examples of single strand-specific nucleases suitable for use in the present invention include S1 nuclease and mung bean nuclease. Thus, the only label detected is that
5 of the probe-oligonucleotide analyte hybrid. Detection and quantitation are via the detectable marker's binding partner(s) and/or substrate(s). For example, an alkaline phosphatase-labeled anti-digoxigenin antibody is used to detect the bound digoxigenin-containing probe.

10 Although digoxigenin is exemplified herein as the detectable marker, the use of any detectable marker capable of being incorporated into an oligonucleotide probe is within the scope of the present invention. Various detectable markers have been discussed in the art and each marker has a
15 well known protocol for its use and detection. Such protocols or approaches can include, but are not limited to, fluorometric measurement, autoradiographic measurement, colorimetric measurement, visual observation, chemiluminescent measurement, electrochemical measurement and the like.

20 Similarly, although the biotin-streptavidin system is used in the examples described herein, any suitable conjugate pair may be used to bind the probe to the solid support, including antibody-coated solid supports and antigen-conjugated probes.

25 In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid or deoxyribonucleic acid. This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent intersugar (backbone) linkages as well as
30 oligonucleotides having non-naturally-occurring portions which function similarly. Such "modified" or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced binding to target, increased
35 stability in the presence of nucleases and an increase in

bioavailability.

Within the concept of "modified" oligonucleotides, the present invention also includes detection of compositions employing oligonucleotide compounds which are chimeric compounds. "Chimeric" oligonucleotide compounds or "chimeras," in the context of this invention, are nucleic acid compounds, particularly oligonucleotides, which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, and/or consist of an oligomeric sequence known to modify complement activation. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide inhibition of gene expression. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothioate oligodeoxynucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art. RNase H-mediated target cleavage is distinct from the use of ribozymes to cleave nucleic acids.

By way of example, such "chimeras" may be "gapmers," i.e., oligonucleotides in which a central portion (the "gap") of the oligonucleotide serves as a substrate for, e.g., RNase H, and the 5' and 3' portions (the "wings") are modified in such a fashion so as to have greater affinity for, or

stability when duplexed with, the target RNA molecule but are
unable to support nuclease activity (e.g., 2'-fluoro- or 2'-
methoxyethoxy-substituted). Other chimeras include
"hemimers," that is, oligonucleotides in which the 5' portion
5 of the oligonucleotide serves as a substrate for, e.g., RNase
H, whereas the 3' portion is modified in such a fashion so as
to have greater affinity for, or stability when duplexed with,
the target RNA molecule but is unable to support nuclease
activity (e.g., 2'-fluoro- or 2'-methoxyethoxy- substituted),
10 or vice-versa.

A number of chemical modifications to oligonucleotides
that confer greater oligonucleotide:RNA duplex stability have
been described by Freier et al. (*Nucl. Acids Res.*, 1997, 25,
4429). Such modifications are preferred for the RNase H-
15 refractory portions of chimeric oligonucleotides and may
generally be used to enhance the affinity of an antisense
compound for a target RNA.

Chimeric modified oligonucleotide compounds may be
formed as composite structures of two or more
20 oligonucleotides, modified oligonucleotides, oligonucleosides
and/or oligonucleotide mimetics as described above, ligand-
oligonucleotide constructs, or complement protein-
oligonucleotide constructs as described herein. Some of these
compounds have also been referred to in the art as hybrids or
25 gapmers. Representative United States patents that teach the
preparation of some of these hybrid structures include, but
are not limited to, U.S. Patent 5,013,830; 5,149,797;
5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133;
5,565,350; 5,623,065; 5,652,355; 5,652,356; 5,955,589 and
30 5,700,922, certain of which are commonly owned, and each of
which is herein incorporated by reference.

Modifications to an oligonucleotide molecule can alter
the concentration of the molecule required to elicit the
effect for which the molecule is designed. Non limiting
35 examples include varying the amount of phosphorothioate

linkages in the oligonucleotide or altering the oligonucleotide base composition and chemistry such as in the preparation of CpG oligodeoxynucleotides as described by Krieg et al. *Nature* 1995.374:546-549, Weiner et al. *Proc. Natl. Acad. Sci. USA* 1997.94:10833-10837, Liu, H. M. et al. *Blood* 1998.15;92(10):3730-3736, Boggs, R.T. et al., *Antisense Nucleic Acid Drug Dev.* 1997.7(5):461-471, and Kline et al. *J. Immunol* 1998.15;160(6):2555-2559.

Also detectable by the methods of the invention are compositions employing oligonucleotides that are substantially chirally pure with regard to particular positions within the oligonucleotides. Examples of substantially chirally pure oligonucleotides include, but are not limited to, those having phosphorothioate linkages that are at least 75% Sp or Rp (U.S. Patent 5,587,361) and those having substantially chirally pure (Sp or Rp) alkylphosphonate, phosphoramidate or phosphotriester linkages (U.S. Patent 5,212,295 and 5,521,302).

Specific examples of some preferred modified oligonucleotides detectable by the present invention include those containing phosphorothioates (P=S oligonucleotides), phosphotriesters, methyl phosphonates, short chain alkyl or cycloalkyl intersugar linkages or short chain heteroatomic or heterocyclic intersugar linkages. Oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

Examples of modified oligonucleotide backbones include phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral

phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having 5 normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Various salts, mixed salts and free acid forms are also included.

10 Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S. Patent 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 15 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

20 Additional examples of modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short 25 chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and 30 thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts.

35 Representative United States patents that teach the

preparation of the above oligonucleosides include, but are not limited to, U.S. Patent 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439, certain of which are commonly owned with this application.

In other example oligonucleotide mimetics, both the 10 sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have 15 excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly 20 or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Patent 5,539,082; 5,714,331; and 5,719,262. Further teaching of PNA compounds can be found in Nielsen et al. 25 *Science* 1991.254, 1497-1500.

Additional examples are oligonucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular $-\text{CH}_2-\text{NH}-\text{O}-\text{CH}_2-$, $-\text{CH}_2-\text{N}(\text{CH}_3)-\text{O}-\text{CH}_2-$ [known as a methylene (methylimino) or MMI 30 backbone], $-\text{CH}_2-\text{O}-\text{N}(\text{CH}_3)-\text{CH}_2-$, $-\text{CH}_2-\text{N}(\text{CH}_3)-\text{N}(\text{CH}_3)-\text{CH}_2-$ and $-\text{O}-\text{N}(\text{CH}_3)-\text{CH}_2-\text{CH}_2-$ [wherein the native phosphodiester backbone is represented as $-\text{O}-\text{P}-\text{O}-\text{CH}_2-$] of the above referenced U.S. Patent 5,489,677, and the amide backbones of the above referenced U.S. Patent 5,602,240. Oligonucleotides having 35 morpholino backbone structures of the above-referenced U.S.

Patent 5,034,506, are also detectable using methods of the present invention.

Modified oligonucleotides may also contain one or more substituted sugar moieties. Example oligonucleotides comprise one of the following at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C1 to C10 alkyl or C2 to C10 alkenyl and alkynyl. Non limiting examples are $O[(CH_2)_nNO]_m$ CH_3 , $O(CH_2)_nOCH_3$, $O(CH_2)_nNH_2$, $O(CH_2)_nCH_3$, $O(CH_2)_nONH_2$, and $O(CH_2)_nON[(CH_2)_nCH_3]_2$, where n and m are from 1 to about 10. Other examples comprise one of the following at the 2' position: C1 to C10 lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH₃, OCN, Cl, Br, CN, CF₃, OCF₃, SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. Other example modifications include 2'-methoxyethoxy (2'-O-CH₂CH₂OCH₃, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., *Helv. Chim. Acta*, 1995, 78, 486-504) i.e., an alkoxyalkoxy group. Modifications which include 2'-dimethylaminoethoxy, i.e., a $O(CH_2)_2ON(CH_3)_2$ group, also known as 2'-DMAOE,, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethylaminoethoxyethyl or 2'-DMAEOE), i.e., 2'-O-CH₂-O-CH₂-N(CH₂)₂.

Additional example modifications include 2'-methoxy (2'-O-CH₃), 2'-aminopropoxy (2'-OCH₂CH₂CH₂NH₂) and 2'-fluoro (2'-F). Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked

oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the
5 preparation of such modified sugar structures include, but are not limited to, U.S. Patent 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873;
10 5,670,633; and 5,700,920, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

Oligonucleotides may also include nucleobase (often referred to in the art simply as "base") modifications or
15 substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-
20 hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-
25 azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-
30 methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in U.S. Patent 3,687,808, those disclosed in *The Concise Encyclopedia Of Polymer Science And Engineering*, pages 858-859, Kroschwitz,
35 J.I. ed. John Wiley & Sons 1990, those disclosed by Englisch

et al. *Angewandte Chemie, International Edition* 1991.30, 613, and those disclosed by Sanghvi, Y.S., Chapter 15, *Antisense Research and Applications* pages 289-302, Crooke, S. T. and Lebleu, B. ed. *CRC Press* 1993. Certain of these nucleobases
5 are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine
10 substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y. S., Crooke, S.T. and Lebleu, B. eds., *Antisense Research and Applications*, *CRC Press*, Boca Raton 1993. pp. 276-278).

Representative United States patents that teach the
15 preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. Patent 3,687,808, as well as U.S. Patent 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908;
20 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; and 5,681,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference, and United States Patent 5,750,692, which is commonly owned with the instant
25 application and also herein incorporated by reference.

Another modification of oligonucleotides detectable by the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake
30 of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al. *Proc. Natl. Acad. Sci. USA* 1989.86, 6553-6556), cholic acid (Manoharan et al. *Bioorg. Med. Chem. Let.* 1994.4:1053-1060), a thioether, e.g., hexyl-S-tritylthiol

(Manoharan et al. *Ann. N.Y. Acad. Sci.* 1992.660:306-309; Manoharan et al. *Bioorg. Med. Chem. Lett.* 1993.3:2765-2770), a thiocholesterol (Oberhauser et al. *Nucl. Acids Res.* 1992.20:533-538), an aliphatic chain, e.g., dodecandiol or undecyl
5 residues (Saison-Behmoaras et al., *EMBO J.* 1991.10:1111-1118; Kabanov et al. *FEBS Lett.* 1990.259:327-330; Svinarchuk et al. *Biochimie* 1993.75:49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al. *Tetrahedron Lett.*
10 1995.36:3651-3654; Shea et al. *Nucl. Acids Res.* 1990.18:3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al. *Nucleosides & Nucleotides* 1995.14:969-973), or adamantane acetic acid (Manoharan et al. *Tetrahedron Lett.* 1995.36:3651-3654), a palmityl moiety (Mishra et al. *Biochim.*
15 *Biophys. Acta* 1995.1264:229-237), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al. *J. Pharmacol. Exp. Ther.* 1996.277:923-937).

Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but
20 are not limited to, U.S. Patent 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717; 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025;
25 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241; 5,391,723; 5,416,203; 5,451,463; 5,510,475;
30 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference.

It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an
5 oligonucleotide.

Further examples of modifications for the oligonucleotides detectable by the present invention involve chemically linking to the oligonucleotide one or more lipophilic moieties which enhance the cellular uptake of the
10 oligonucleotide. Such lipophilic moieties may be linked to an oligonucleotide at several different positions on the oligonucleotide. Some non-limiting example positions include the 3' position of the sugar of the 3' terminal nucleotide, the 5' position of the sugar of the 5' terminal nucleotide,
15 and the 2' position of the sugar of any nucleotide. The N6 position of a purine nucleobase may also be utilized to link a lipophilic moiety to an oligonucleotide of the invention (Gebeyehu, G. et al. *Nucleic Acids Res.* 1987.15:4513). Such lipophilic moieties include but are not limited to a
20 cholesteryl moiety (Letsinger et al. *Proc. Natl. Acad. Sci. USA* 1989.86:6553), cholic acid (Manoharan et al. *Bioorg. Med. Chem. Lett.* 1994.4:1053), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al. *Ann. N.Y. Acad. Sci.* 1992. 660:306; Manoharan et al. *Bioorg. Med. Chem. Lett.* 1993.3:2765),
25 a thiocholesterol (Oberhauser et al. *Nucl. Acids Res.* 1992. 20:533), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al. *EMBO J.* 1991.10:111; Kabanov et al. *FEBS Lett.* 1990.259:327; Svinarchuk et al. *Biochimie* 1993.75:49), a phospholipid, e.g., di-hexadecyl-rac-glycerol
30 or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al. *Tetrahedron Lett.* 1995.36:3651; Shea et al. *Nucl. Acids Res.* 1990.18:3777), a polyamine or a polyethylene glycol chain (Manoharan et al. *Nucleosides & Nucleotides* 1995.14:969), or adamantane acetic acid (Manoharan

et al. *Tetrahedron Lett.* 1995.36:3651), a palmityl moiety (Mishra et al. *Biochim. Biophys. Acta* 1995.1264:229), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al. *J. Pharmacol. Exp. Ther.* 1996.277:923).

- 5 Oligonucleotides comprising lipophilic moieties, and methods for preparing such oligonucleotides, as disclosed in U.S. Patent 5,138,045, 5,218,105 and 5,459,255, the contents of which are hereby incorporated by reference in their entirety.

In other examples the compound to be detected may be a
10 ligand conjugated oligomeric compound having improved pharmacokinetic properties. Such oligomeric compounds are prepared having covalently attached ligands or proteins that bind reversibly to or interact with one or more serum, vascular or cellular proteins. This reversible binding is
15 expected to decrease urinary excretion, increase serum half life and greatly increase the distribution of oligomeric compounds thus conjugated. The binding of particular drugs to plasma protein has been previously shown to enhance the disposition and efficacy of drugs (Herve et al. *Clin.*
20 *Pharmacokinet.* 1994.26:44).

Many drugs reversibly bind to plasma proteins. A representative list, which is not meant to be inclusive, includes: aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fenbufen, ketoprofen, (S)-(+)-pranoprofen,
25 carprofen, dansylsarcosine, 2,3,5-triiodobenzoic acid, flufenamic acid, folinic acid, benzothiadiazides, chlorothiazide, diazepines (such as for example fludiazepam and diazepam) indomethacin, barbiturates (such as for example quinalbarbitone), cephalosporins, sulfa drugs, antidiabetics
30 (such as for example tolbutamide), antibacterials (such as for example a group of quinolones; nalidixic acid and cinoxacin) and several antibiotics. Serum albumin is the most important protein among all plasma proteins for drug binding, although binding to other proteins (for example, macroglobulin G2,
35 immunoglobulins, lipoproteins, alpha-1-acid glycoprotein,

thrombin) is also important.

Ligands such as the above drugs that bind serum, vascular or cellular proteins may be attached via an optional linking moiety to one or more sites on an oligonucleotide to be administered to a subject and detected in accordance with the present invention. These sites include one or more of, but are not limited to, the 2'-position, 3'-position, 5'-position, the internucleotide linkage, and a nucleobase atom of any nucleotide residue. The attachment of ligands to such structures can be performed, according to some preferred embodiments of the invention, using a linking group, or without the use of such a linking group. Example linking groups include, 6-aminoalkoxy linkers, 6-aminoalkylamino linkers, cysteamine, heterobifunctional linkers, homobifunctional linkers, and a universal linker (derived from 3-dimethoxytrityloxy-2-aminopropanol). A particularly preferred linking group for the synthesis of ligand conjugated oligonucleotides of the invention is a 6-aminohexyloxy group. A variety of heterobifunctional and homobifunctional linking moieties are available from Pierce Co. (Rockford, IL). Such heterobifunctional and homobifunctional linking moieties are particularly useful in conjunction with the 6-aminoalkoxy and 6-aminoalkylamino moieties to form extended linkers useful for linking ligands to a nucleoside. Further useful linking groups that are commercially available are 5'-Amino-Modifier C6 and 3'-Amino-Modifier reagents, both available from Glen Research Corporation (Sterling, VA). 5'-Amino-Modifier C6 is also available from ABI (Applied Biosystems Inc., Foster City, CA) as Aminolink-2, while the 3'-Amino-Modifier is also available from Clontech Laboratories Inc. (Palo Alto, CA). In addition, a nucleotide analog bearing a linking group pre-attached to the nucleoside is commercially available from Glen Research Corporation under the trade name "Amino-Modifier-dT." This nucleoside-linking group reagent, a uridine derivative having an [N(7-trifluoroacetylaminoheptyl)3-acrylamido]

substituent group at the 5 position of the pyrimidine ring, is synthesized as per the procedure of Jablonski et al. (*Nucleic Acid Research*, 1986, 14:6115).

Ligand conjugated oligonucleotides may be synthesized
5 by the use of an oligonucleotide that bears a pendant reactive functionality such as that derived from the attachment of a linking molecule onto the oligonucleotide. This reactive oligonucleotide may be reacted directly with commercially available ligands, ligands that are synthesized bearing a
10 variety of protecting groups, or ligands that have a linking moiety attached thereto.

The oligonucleotides detectable in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for
15 such synthesis is sold by several vendors including Applied Biosystems. Any other means for such synthesis may also be employed; the actual synthesis of the oligonucleotides is well within the talents of the routineer. It is well known to use similar techniques to prepare oligonucleotides such as the
20 phosphorothioates and 2'-alkoxy or 2'-alkoxyalkoxy derivatives, including 2'-O-methoxyethyl oligonucleotides (Martin, P., *Helv. Chim. Acta*, 1995, 78, 486-504). It is also well known to use similar techniques and commercially available modified amidites and controlled-pore glass (CPG)
25 products such as biotin, fluorescein, acridine or psoralen-modified amidites and/or CPG (available from Glen Research, Sterling VA) to synthesize fluorescently labeled, biotinylated or other conjugated oligonucleotides.

By the terms "administered" or "administered" is meant
30 providing to a subject a modified oligonucleotide. Administration may be topical (including ophthalmic, vaginal, rectal, intranasal, epidermal and transdermal), oral or parenteral, needle injection, needle-free injection as in, for example, an injection using a device like the Medi-Jector(tm),
35 and by aliquots using a pipette. Parenteral administration

includes intravenous drip or infusion, subcutaneous, intraperitoneal or intramuscular injection, pulmonary administration, e.g., by inhalation or insufflation, or intracranial, e.g., intrathecal or intraventricular, 5 administration. Modes of administering oligonucleotides are disclosed in U.S. Patent 6,083,923, the entire contents of which are incorporated herein by reference.

Formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, 10 suppositories, sprays, liquids and powders.

Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders.

15 Compositions for parenteral administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives. Methods for providing a compound to a subject are well known and are not considered limiting aspects of the present invention. Furthermore, the 20 site or target of administration is also not considered a limiting aspect to the present invention.

"Subject" as used herein refers to a mammal that has been administered a modified oligonucleotide. Non-limiting examples of mammals of the invention include rodent, 25 lagomorph, porcine, canine, feline, and primate. In a preferred embodiment the mammal is a primate and most preferably the mammal is a human.

As used herein "detect" or "detected" means the instrumental measurement or visual observation of the 30 detectable label as indicative of the presence of the synthetic modified oligonucleotide in the obtained bodily fluid and/or extract sample.

By the phrase "obtain(ing) a sample" is meant the extraction or separation of a bodily fluid and/or extract from 35 the subject. Approaches for obtaining, extracting, excising,

lancing, dissecting, excreting, evacuating bodily fluid and/or extracts from a subject or by a subject, are well known and have been practiced or requested by nurses, physicians and research scientists. The approach used to obtain the bodily
5 fluid and/or extract is not considered a limiting aspect of the present invention.

In the context of the present invention "bodily fluid and/or extract" refers to any bodily substance removed from the subject to be screened for the presence of an
10 oligonucleotide. While it is understood that some portions of the body are not readily assayed as a fluid, procedures to homogenize and prepare liquid samples from those portions are not uncommon, and are well known. The addition of water or saline to body portions which are normally not liquid is
15 within the scope of the present invention, for example, a homogenized sample of a bone suspension, can be assayed by the methods described herein. Thus, the bodily fluid and/or extract may be prepared, or may be selected from, but not limited to, the following; tissue, bone or organ samples,
20 serum, saliva, feces, tears, sweat, and samples of blood cells, epithelial cells, and the like.

By "probe" is meant an oligonucleotide or polynucleotide configured and arranged to bind the target modified oligonucleotide molecule that has been administered to the
25 subject. Preferably, the probe sequence is substantially complementary to at least a portion of the target nucleic acid sequence and is configured to contain a detectable marker. A "capture probe" is a probe containing a moiety for binding to a solid support, such as biotin, which binds strongly and
30 specifically to streptavidin-coated solid supports such as beads, culture dishes or 96 well plates, for example, allowing "capture" of the oligonucleotide to be detected onto a solid support.

"Detectable marker" as used herein refers to that
35 component or moiety attached to a probe or a component of the

probe, which is capable of interacting with and/or binding, directly or indirectly, to a detectable label. In nonlimiting examples, detectable markers include nucleic acids conjugated to a member of a binding pair or substrates for enzymatic reactions such as digoxigenin or a series of nucleotides of known (homogeneous or heterogeneous) sequence, e.g. polyA.

By the term "detectable label" is meant a compound and/or molecule that is observable by either visual or mechanical means. In nonlimiting examples, bifluoro-
10 chromophores, radioactive isotopes, chemiluminescent or chromogenic labels presently available may be used as detectable labels. The detectable label and the manner by which the label is monitored are not considered to be limiting factors of the present invention. The detectable label can
15 be part of a binding pair such as for example biotin-streptavidin, digoxigenin conjugated to alkaline phosphatase or other antigen-antibody complexes. The detectable label offers a way to determine the presence of the modified oligonucleotide via positive interaction with the probe.

20 The following examples illustrate aspects the present invention and are not intended to limit the same. Although the examples presented below relate to detection of particular oligonucleotides using the methods of the present invention, any oligonucleotide having a known sequence may be detected
25 using a probe which has a complementary sequence.

Example 1 Oligonucleotide detection assay method

The desired volume of oligonucleotide (analyte)-containing plasma (100 μ l) was aliquoted into 96-well plates.
30 To every 100 μ L of human or monkey plasma, 5 μ L of 10% NP-40 was added.

Plasma standard curve and quality control (QC) samples were prepared as follows. Equivalent volumes of control blank plasma (90 μ L) from untreated animals or humans were aliquoted
35 into the appropriate number of wells as specified below. Ten

μ L of the appropriate concentration of oligonucleotide were added to the plasma on the plate as specified below. Calibration standards and QC samples were distributed evenly among the study samples. A minimum of six non-zero
5 concentrations in duplicate bracketing the expected concentration range of unknown samples were used as standard curve points. The analyte oligonucleotide was added to plasma to achieve the desired concentrations. Three concentrations of QC standard were prepared (low, medium and high) in at
10 least duplicate. The low QC was near the limit of quantitation (LOQ) concentration (i.e., $(3 \times \text{LOQ})$). The medium QC was about midway between the high and low QC concentrations. The high QC was at 75 to 90% of the highest calibration standard. A minimum of three matrix blanks and
15 two water blanks was run with each plate of sample analysis. The plate was vortexed on an Ambi-Hi-Lo incubator (VWR Scientific) for about 5 seconds to mix.

To the plasma samples, calibration standard, QC samples and blanks, 100 μ L of Cutting Probe Working Solution (0.05 μ M
20 template probe complementary to the analyte in 60 mM Na_2HPO_4 , pH 7.4, 0.9 M NaCl, 0.24% Tween-20) was added and the plate was incubated at 37°C for one hour. The 3'-end of the probe is biotinylated and the 5'-end is labeled with digoxigenin (Operon Technologies, Inc.). 150 μ L of this hybridization
25 solution was transferred onto Reacti-Bind™ NeutrAvidin Coated Polystyrene Strip Plates (Clear) (Pierce Chemical Co.) using a multi-channel pipette, and the plate was incubated at 37°C for 30 minutes. After incubation, the plate was refrigerated (4-8°C) for about 10 minutes. The plate was then washed four
30 times with 1XTBS/Tween (25 mM Tris-HCl, pH 7.2, 0.15 M NaCl, 0.1% Tween-20).

To each well was added 300 μ L S1 nuclease solution (50 units/mL of S1 nuclease (Life Technologies) in 30 mM sodium acetate, pH 4.6, 1 mM ZnCl_2 , 5% (v/v) glycerol, and the plate
35 was incubated at room temperature for two hours, then washed

four times with 1XTBS/Tween. Anti-digoxigenin-alkaline phosphatase (AP) working solution (1:2000 dilution of Anti-digoxigenin-AP, Fab fragments (Boehringer Mannheim). (150 μ L) was added to each well and the plate was incubated at room temperature for 30 minutes. The wells were then washed five times with 1XTBS/Tween. ATTOPHOS Working Solution (60 mL of ATTOPHOS reconstitution solution (JBL Scientific) mixed with 36 mg ATTOPHOS(fluorescent substrate (JBL Scientific)). 150 μ L was added at 10 second increments per row/column. The plate was incubated at 37°C for 10-20 minutes until fluorescence of the most concentrated calibration point reached 18000-23000 at 45 gain. Stop solution (70 μ L of 25% $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ in water (w/v)) was then added at 10 second increments per row/column in the same order as was the ATTOPHOS solution. The plate was read in a fluorescence plate reader (CytoFluor) with the excitation set at 450/50 and the emission at 580/80 at gain of 45 and 42.

Example 2 Selectivity for metabolites

A plate was prepared and concentrations of the following metabolites were measured by the method described in Example 1: N-1 from the 3'-end of ISIS 104838, N-1 from the 3'-end of ISIS 2302 and N-1 from the 5'-end of ISIS 2302. Full-length ISIS 2302 and 104838 were also measured. The results are shown in Fig. 3. All oligonucleotides were detected by the method and produced linear results, although the response for the metabolites was slightly less. Thus, the assay is not selective to metabolites or full length oligonucleotide.

Example 3 Detection of 2'-MOE oligonucleotides

Concentrations of the following 2'-methoxyethyl (2'-MOE) were measured by the method describe in Example 1: ISIS 104838 (SEQ ID NO: 1), ISIS 22023 (SEQ ID NO: 3) and ISIS 113715 (SEQ ID NO:4). Complementary oligonucleotide probes labeled at the 3'-end with digoxigenin and the 5'-end with

biotin were used to detect each analyte. The results are shown in Fig. 4. All three oligonucleotides showed linearity.

Example 4 Validation of ISIS 22023 in mouse plasma

5 ISIS 22023 was added to mouse plasma to obtain concentrations of 50 pM, 100 pM, 500 pM and 1500 pM. To validate the assay, the protocol described in Example 1 was used to quantitate ISIS 22023 at each of these concentrations. Six replicates of each concentration were analyzed. The
10 results are shown in Table 1. The assay showed good accuracy and precision. The "mean" column indicates the mean concentration of oligonucleotide determined by the assay for the six replicates.

15 **Table 1**

ID	Nominal conc., pM	Mean	SD	Accuracy	%relative SD (RSD)
LOQ	50	52	49	103.4	19.2
Low QC	10	85	15	84.9	17.9
Mid QC	500	571	63	114.2	11.0
20 High QC	1500	1661	158	110.7	9.5

Example 5

Detection of ISIS 22023 after injection in mice
ISIS 22023 (50 mg/kg) was injected subcutaneously into mice
25 and the plasma concentration was determined at various times post-injection by the method described in Example 1. The results are shown in Fig. 5. ISIS 2302 had a very long elimination half-life. The predicted and observed half lives corresponded very well.

30

Example 6 ISIS 104838 Stability studies

Multiple storage vials containing ISIS 104838 at concentrations of 100 pM, 500 pM and 1500 pM were prepared in

monkey plasma and stored at -80°C . To determine freeze-thaw stability, replicates at each concentration were studied after cycles of 1 and 3 freeze-thaws. For determination of short-term room temperature stability, replicates at each concentration were kept at room temperature for 24 hours. The results (Tables 2 and 3; F-T=freeze-thaw) show that ISIS 104838 appeared stable for 24 hours at room temperature in monkey plasma, was stable for 1 day at -80°C , and were stable through freeze-thaw cycles. Results were consistent among freeze-thaw samples and 10-day storage samples.

Table 2

ID	Storage Time	Conc., pM	Accuracy	%RSD
Low QC	24 hr, RT	100	157.9	21.31
Medium QC	24 hr, RT	500	124.6	6.58
High QC	24 hr, RT	1500	96.3	7.12
Low QC	1 F-T	100	109.9	18.90
Medium QC	1 F-T	500	119.1	7.00
High QC	1 F-T	1500	92.9	7.60

Table 3

ID	Storage Time	Conc., pM	Calc. Conc., pM	Accuracy	%RSD
Low QC	3 F-T	100	168	167.6	15.38
Medium QC	3 F-T	500	672	134.3	3.98
High QC	3 F-T	1500	1516	101.0	1.76
Low QC	10 day freezer	100	164	164.2	13.5
Medium QC	10 day freezer	500	715	143.0	22.89
High QC	10-day freezer	1500	1545	103.0	5.01

Example 7 Stability of ISIS 104838 in human plasma

ISIS 104838 was stored at about 20°C and protected from light. The purity of the reference standard was measured by capillary gel electrophoresis and was found to be 99.807%.

5 All samples were analyzed using cutting assay described in Example 1.

Stability of ISIS 104838 in human plasma was studied at nominal values of low (300 pM), medium (750 pM) and high (1500 pM) oligonucleotide concentrations. The actual concentrations
10 determined right after sample preparation were 369, 901 and 1857 pM for low, medium and high, respectively. Room temperature, freeze/thaw and long term freezer storage stability were performed. The samples were stable stored at
15 1 and 24 hr at room temperature (81.3-122.7 of expected concentrations) at all the concentrations examined (Table 4). Following freezer storage at -70°C for 7 days, the samples were also stable (83.9-104.9% of expected concentrations) (Table 5). Following one freeze/thaw cycle, the observed
20 concentration at 369 pM was 52.2% higher than the expected concentration and the observed concentration was in the range of 99.5-120% of expected concentrations at 901 and 1857 pM (Table 6).

Table 4

25	Storage time	Conc. Spiked (pM)	Observed conc. (mean±SD)	%Nominal	%CV
	1 hr	369	300±14	81.3	4.52
		901	775±31	86.0	3.97
		1857	1507±45	81.2	3.01
30	24 hr	369	453±23	122.7	5.15
		901	908±29	100.7	3.22
		1857	1582±50	85.2	3.16

Table 5

Conc. Spiked (pM)	Observed conc. (pM) (mean \pm SD)	%Nominal	%CV
369	387 \pm 29	104.9	7.56
901	810 \pm 125	89.8	15.4
1857	1558 \pm 90	83.9	5.81

Table 6

Conc. Spiked (pM)	Observed conc. (pM) (mean \pm SD)	%Nominal	%CV
369	561 \pm 43	152.2	7.57
901	1082 \pm 77	120.0	7.16
1857	1847 \pm 44	99.5	2.38

Example 8 Specificity

Control human plasma from ten subjects was analyzed in triplicate for possible endogenous interference. As shown in Table 5, plasma from all subjects had a response less than 50% of the response at the LOQ (100 pM). A linear range of 100 pM (0.1 nM) to 20,000 pM (20 nM) ($r \geq 0.98$) was obtained in human plasma for ISIS 104838. Therefore, no interference was noted from the human plasma.

Table 7

Subject #	Calc. Conc. (pM) Equivalent to ISIS 104838 (Mean \pm SD)	%LOQ
1	4594 \pm 1.32	45.94
2	50.89 \pm 0.64	50.89
3	47.92 \pm 4.65	47.92
4	44.85 \pm 2.81	44.85
5	46.58 \pm 3.61	46.58

6	37.47±5.71	37.47
7	40.65±2.66	40.65
8	42.18±2.12	42.18
9	41.28±2.72	41.28
5 10	37.54±1.38	37.54

Example 9 Calibration curves

Calibration curves (100 to 2000 pM) and 1 to 20 nM) in human plasma were run by two analysts on three different days. Each calibration curve was run in duplicate at concentrations of 100, 200, 500, 1000, 1500, and 2000 pM for the low curve, and 1, 2, 5, 10, 15, 20 nM for the high curve. Each curve was fitted to log/log linear curve without weighting. Representative high and low calibration curves are shown in Figures 6 and 7, respectively. Correlation coefficients for ISIS 104838 were found to be greater than or equal to 0.98 for all calibration curves. Therefore, an acceptable linearity was achieved at concentrations from 100 pM to 20 nM for ISIS 104838 in human plasma.

Example 10 Intra-day accuracy and precision

Six replicate QC samples at four concentrations were used to evaluate intra-day accuracy and precision. The concentrations evaluated were LOQ (100 pM), low (300 pM), medium (750 pM), high (1500 pM) QC and dilution QC (10,000 pM, dilution 1:10) samples performed in human plasma. A 1:10 dilution with blank human plasma was made for the dilution QC sample prior to sample analysis. Intra-day analysis was performed on three different days by two different analysts. Concentrations of ISIS 104838 from the LLOQ, low, medium, high and diluted QC samples were analyzed using the following calibration curve method (Equation 1)

$$\text{Log}_{10}(C_2) = \text{Log}_{10}(\text{Flu}) - \text{intercept/slope} \quad (1)$$

Where C_2 =concentration of the analyte (ISIS 104838),
Flu=fluorescence reading of the analyte, intercept and slope
were from linear regression of the calibration curve.
Accuracy for the QC samples was calculated as the percentage
5 of the calculated concentrations compared to the nominal
concentrations for ISIS 104838 (%Actual). Precision was
expressed as coefficient of variation (%CV). The results for
Days 1 to 3 intra-day accuracy are shown in Tables 8a-8c,
respectively.

10

Table 8a

ID	Nominal conc. (pM)	Calc. Conc. (pM) (mean±SD)	%Actual	%CV
LOQ	100	91±14	90.8	15.1
Low QC	300	353±28	117.7	8.1
15 Mid QC	750	839±52	111.8	6.2
High QC	1500	1456±37	97.1	2.5
Dilution QC	10000	10215±631	102.2	6.2

20

Table 8b

ID	Nominal conc. (pM)	Calc. Conc. (pM) (mean±SD)	%Actual	%CV
LOQ	100	82±11	81.6	13.7
Low QC	300	310±30	103.4	9.8
25 Mid QC	750	793±71	105.7	8.9
High QC	1500	1486±92	99.1	6.2
Dilution QC	10000	9893±496	98.9	5.0

30

Table 8c

ID	Nominal conc. (pM)	Calc. Conc. (pM) (mean \pm SD)	%Actual	%CV
LOQ	100	93 \pm 20	93.3	21.8
Low QC	300	223 \pm 36	74.4	16.2
Mid QC	750	741 \pm 149	98.8	20.1
High QC	1500	1584 \pm 173	105.6	10.9
Dilution QC	10000	9364 \pm 1758	93.6	18.8

10

Acceptable assay accuracy was achieved for LOQ, low, mid, high and dilution QC (in the range of 90.8-117.7% of nominal spiked concentrations on Day 1, 81.6-105.7% on Day 2, 93.3-105.6% on Day 3) with the exception of the low QC on Day 3, where the %Actual was 74.4%. Therefore, the accuracy acceptance criteria was generally met (75-125% at LOQ and 80-120% at other QC levels). Acceptable intra-day precision (expressed as coefficient of variation, %CV) was less than 21.8% and less than 20.1% for LOQ and QC samples, respectively, which met the acceptance criteria (<25% at LOQ and <20% at other QC levels).

Example 11 Inter-day precision and accuracy

Inter-day accuracy and precision were calculated from the pooled data of QC using 18 replicates of QC samples each at five different concentrations (100, 300, 750, 1500 and 10,000 pM) performed on three different days by two analysts. Acceptable inter-day assay accuracy was achieved for the quantitation of ISIS 104838 (in the range of 88.6%-105.5% of nominal spiked concentrations over the concentration range studied) (Table 9). Acceptable inter-day assay precision was also obtained (%CV \leq 21.4%), which met the precision acceptance criteria. The dilution QC had an inter-day accuracy at 98.2% with %CV of 11.3%, which met the precision acceptance

criteria. The inter-day data showed that the method was reproducible in different days and across multiple analysts.

Table 9

5

ID	Nominal conc. (pM)	Observed Conc. (pM) (mean±SD)	%Actual	%CV
LOQ	100	89±16	88.6	17.5
Low QC	300	296±63	98.5	21.4
Mid QC	750	791±102	105.5	12.9
High QC	1500	1509±122	100.6	8.1
Dilution QC	10000	9824±1109	98.2	11.3

10

Example 12 Cross-validation to high range in human plasma

15

In order to determine samples at higher calibration range, a one-day cross-validation at a high range was conducted. In this validation procedure, a six-point calibration standard from 1 nM to 20 nM (at 1, 2, 5, 10, 15 and 20 nM) in duplicate was prepared and analyzed by the cutting assay described in Example 1. Accuracy and precision were assessed with QC samples in six replicates at 2 nM (LLOQ), 5 nM (low QC), 10 nM (medium QC) and 15 nM (high QC) prepared in human plasma. To verify the accuracy and precision of dilution samples, an extra high QC sample (containing 1000 nM of ISIS 104838) in human plasma was prepared in six replicates. A 1:100 dilution with blank human plasma was made for this QC sample prior to sample analysis. For sample preparation of the calibration standards and QC samples, 12.5 µl of standard solution was spiked into 12.5 µl of human plasma and 100 µl of distilled water.

20

25

30

The linear range for the high curve was 1 to 20 nM with $r^2 \geq 0.98$. As shown in Table 10, the accuracy and precision for the LOQ, low, medium and high QC had an %Actual in the range

of 108.3-119.1% with %CV≤10.0%, which met the established accuracy and precision acceptance criteria. The dilution QC had an accuracy of 117.4% with %CV of 6.4%, which also met the accuracy and precision acceptance criteria. In summary, the cross-validation to a high calibration range indicated that the assay was accurate and precise for the quantitation of ISIS 104838 at concentrations between 1 and 20 nM with dilution samples up to 1000 nM (1 μM) in human plasma.

10

Table 10

ID	Nominal conc. (nM)	Calc. Conc. (nM) (mean±SD)	%Actual	%CV
LOQ	2	2.27±0.23	113.6	10.0
Low QC	5	5.77±0.27	115.3	4.7
Mid QC	10	11.91±0.70	119.1	5.9
High QC	15	16.24±0.37	108.3	2.3
Dilution QC	1000	1174±75	117.4	6.4

15

20

In summary, the assay was specific, accurate, precise and sensitive for the quantitation of ISIS 104838 in human plasma. Moreover, the method was reproducible by multiple analysis.

What is Claimed is:

1. A method for detecting or quantitating an oligonucleotide in a bodily fluid or extract, comprising the
5 steps of:

contacting said fluid or extract with a probe complementary to said oligonucleotide, wherein said probe comprises a detectable marker and a binding moiety;

10 placing said fluid or extract in contact with a solid support to which a binding partner of said binding moiety is attached;

contacting said fluid or extract with a single-strand specific nuclease under conditions in which probe which is not hybridized to said oligonucleotide is degraded; and

15 detecting a label associated with said marker, wherein the presence of said label indicates the presence of said oligonucleotide bound to said solid support.

2. The method of Claim 1, wherein said bodily fluid is
20 plasma.

3. The method of Claim 1, wherein said oligonucleotide comprises at least one phosphorothioate linkage.

25 4. The method of Claim 1, wherein said oligonucleotide comprises a modification at the 2' position of at least one sugar moiety.

5. The method of Claim 4, wherein said 2' modification
30 is a 2'-O-methoxyethyl modification.

6. The method of Claim 1, wherein said oligonucleotide comprises at least one modified base.

35 7. The method of Claim 6, wherein said modified base is

5-methylcytosine.

8. The method of Claim 1, wherein said marker is digoxigenin.

5

9. The method of Claim 1, wherein said label is a colorimetric, radioactive, chemiluminescent, enzymatic or fluorescent label.

10 10. The method of Claim 1, wherein said single-strand specific nuclease is S1 nuclease or mung bean nuclease.

11. The method of Claim 1, wherein said oligonucleotide is exogenously administered.

15

ABSTRACT

A method for quantitating an oligonucleotide in a sample of bodily fluid and/or extract is provided. The method
5 comprises contacting an oligonucleotide with a probe comprising a detectable marker and a binding moiety; placing the fluid or extract in contact with a solid support to which a binding partner of the binding moiety is attached; contacting the fluid or extract with a single-strand specific
10 nuclease to degrade probe which is not hybridized to the oligonucleotide; and detecting a label associated with the marker. The method provides for the detection and/or localization of oligonucleotides, including administered modified oligonucleotides, for therapeutic and/or
15 pharmacokinetic purposes.

thrombin) is also important.

Ligands such as the above drugs that bind serum, vascular or cellular proteins may be attached via an optional linking moiety to one or more sites on an oligonucleotide to be administered to a subject and detected in accordance with the present invention. These sites include one or more of, but are not limited to, the 2'-position, 3'-position, 5'-position, the internucleotide linkage, and a nucleobase atom of any nucleotide residue. The attachment of ligands to such structures can be performed, according to some preferred embodiments of the invention, using a linking group, or without the use of such a linking group. Example linking groups include, 6-aminoalkoxy linkers, 6-aminoalkylamino linkers, cysteamine, heterobifunctional linkers, homobifunctional linkers, and a universal linker (derived from 3-dimethoxytrityloxy-2-aminopropanol). A particularly preferred linking group for the synthesis of ligand conjugated oligonucleotides of the invention is a 6-aminohexyloxy group. A variety of heterobifunctional and homobifunctional linking moieties are available from Pierce Co. (Rockford, IL). Such heterobifunctional and homobifunctional linking moieties are particularly useful in conjunction with the 6-aminoalkoxy and 6-aminoalkylamino moieties to form extended linkers useful for linking ligands to a nucleoside. Further useful linking groups that are commercially available are 5'-Amino-Modifier C6 and 3'-Amino-Modifier reagents, both available from Glen Research Corporation (Sterling, VA). 5'-Amino-Modifier C6 is also available from ABI (Applied Biosystems Inc., Foster City, CA) as Aminolink-2, while the 3'-Amino-Modifier is also available from Clontech Laboratories Inc. (Palo Alto, CA). In addition, a nucleotide analog bearing a linking group pre-attached to the nucleoside is commercially available from Glen Research Corporation under the trade name "Amino-Modifier-dT." This nucleoside-linking group reagent, a uridine derivative having an [N(7-trifluoroacetylaminoheptyl)3-acrylamido]

substituent group at the 5 position of the pyrimidine ring, is synthesized as per the procedure of Jablonski et al. (*Nucleic Acid Research*, 1986, 14:6115).

Ligand conjugated oligonucleotides may be synthesized
5 by the use of an oligonucleotide that bears a pendant reactive functionality such as that derived from the attachment of a linking molecule onto the oligonucleotide. This reactive oligonucleotide may be reacted directly with commercially available ligands, ligands that are synthesized bearing a
10 variety of protecting groups, or ligands that have a linking moiety attached thereto.

The oligonucleotides detectable in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for
15 such synthesis is sold by several vendors including Applied Biosystems. Any other means for such synthesis may also be employed; the actual synthesis of the oligonucleotides is well within the talents of the routineer. It is well known to use similar techniques to prepare oligonucleotides such as the
20 phosphorothioates and 2'-alkoxy or 2'-alkoxyalkoxy derivatives, including 2'-O-methoxyethyl oligonucleotides (Martin, P., *Helv. Chim. Acta*, 1995, 78, 486-504). It is also well known to use similar techniques and commercially available modified amidites and controlled-pore glass (CPG)
25 products such as biotin, fluorescein, acridine or psoralen-modified amidites and/or CPG (available from Glen Research, Sterling VA) to synthesize fluorescently labeled, biotinylated or other conjugated oligonucleotides.

By the terms "administered" or "administered" is meant
30 providing to a subject a modified oligonucleotide. Administration may be topical (including ophthalmic, vaginal, rectal, intranasal, epidermal and transdermal), oral or parenteral, needle injection, needle-free injection as in, for example, an injection using a device like the Medi-Jector(tm),
35 and by aliquots using a pipette. Parenteral administration,

includes intravenous drip or infusion, subcutaneous, intraperitoneal or intramuscular injection, pulmonary administration, e.g., by inhalation or insufflation, or intracranial, e.g., intrathecal or intraventricular, 5 administration. Modes of administering oligonucleotides are disclosed in U.S. Patent 6,083,923, the entire contents of which are incorporated herein by reference.

Formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, 10 suppositories, sprays, liquids and powders.

Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders.

15 Compositions for parenteral administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives. Methods for providing a compound to a subject are well known and are not considered limiting aspects of the present invention. Furthermore, the 20 site or target of administration is also not considered a limiting aspect to the present invention.

"Subject" as used herein refers to a mammal that has been administered a modified oligonucleotide. Non-limiting examples of mammals of the invention include rodent, 25 lagomorph, porcine, canine, feline, and primate. In a preferred embodiment the mammal is a primate and most preferably the mammal is a human.

As used herein "detect" or "detected" means the instrumental measurement or visual observation of the 30 detectable label as indicative of the presence of the synthetic modified oligonucleotide in the obtained bodily fluid and/or extract sample.

By the phrase "obtain(ing) a sample" is meant the extraction or separation of a bodily fluid and/or extract from 35 the subject. Approaches for obtaining, extracting, excising,

lancing, dissecting, excreting, evacuating bodily fluid and/or extracts from a subject or by a subject, are well known and have been practiced or requested by nurses, physicians and research scientists. The approach used to obtain the bodily
5 fluid and/or extract is not considered a limiting aspect of the present invention.

In the context of the present invention "bodily fluid and/or extract" refers to any bodily substance removed from the subject to be screened for the presence of an
10 oligonucleotide. While it is understood that some portions of the body are not readily assayed as a fluid, procedures to homogenize and prepare liquid samples from those portions are not uncommon, and are well known. The addition of water or saline to body portions which are normally not liquid is
15 within the scope of the present invention, for example, a homogenized sample of a bone suspension, can be assayed by the methods described herein. Thus, the bodily fluid and/or extract may be prepared, or may be selected from, but not limited to, the following; tissue, bone or organ samples,
20 serum, saliva, feces, tears, sweat, and samples of blood cells, epithelial cells, and the like.

By "probe" is meant an oligonucleotide or polynucleotide configured and arranged to bind the target modified oligonucleotide molecule that has been administered to the
25 subject. Preferably, the probe sequence is substantially complementary to at least a portion of the target nucleic acid sequence and is configured to contain a detectable marker. A "capture probe" is a probe containing a moiety for binding to a solid support, such as biotin, which binds strongly and
30 specifically to streptavidin-coated solid supports such as beads, culture dishes or 96 well plates, for example, allowing "capture" of the oligonucleotide to be detected onto a solid support.

"Detectable marker" as used herein refers to that
35 component or moiety attached to a probe or a component of the

probe, which is capable of interacting with and/or binding, directly or indirectly, to a detectable label. In nonlimiting examples, detectable markers include nucleic acids conjugated to a member of a binding pair or substrates for enzymatic reactions such as digoxigenin or a series of nucleotides of known (homogeneous or heterogeneous) sequence, e.g. polyA.

By the term "detectable label" is meant a compound and/or molecule that is observable by either visual or mechanical means. In nonlimiting examples, bifluoro-
chromophores, radioactive isotopes, chemiluminescent or chromogenic labels presently available may be used as detectable labels. The detectable label and the manner by which the label is monitored are not considered to be limiting factors of the present invention. The detectable label can be part of a binding pair such as for example biotin-streptavidin, digoxigenin conjugated to alkaline phosphatase or other antigen-antibody complexes. The detectable label offers a way to determine the presence of the modified oligonucleotide via positive interaction with the probe.

The following examples illustrate aspects the present invention and are not intended to limit the same. Although the examples presented below relate to detection of particular oligonucleotides using the methods of the present invention, any oligonucleotide having a known sequence may be detected using a probe which has a complementary sequence.

Example 1 Oligonucleotide detection assay method

The desired volume of oligonucleotide (analyte)-containing plasma (100 μ l) was aliquoted into 96-well plates. To every 100 μ L of human or monkey plasma, 5 μ L of 10% NP-40 was added.

Plasma standard curve and quality control (QC) samples were prepared as follows. Equivalent volumes of control blank plasma (90 μ L) from untreated animals or humans were aliquoted into the appropriate number of wells as specified below. Ten

μ L of the appropriate concentration of oligonucleotide were added to the plasma on the plate as specified below. Calibration standards and QC samples were distributed evenly among the study samples. A minimum of six non-zero
5 concentrations in duplicate bracketing the expected concentration range of unknown samples were used as standard curve points. The analyte oligonucleotide was added to plasma to achieve the desired concentrations. Three concentrations of QC standard were prepared (low, medium and high) in at
10 least duplicate. The low QC was near the limit of quantitation (LOQ) concentration (i.e., $(3 \times \text{LOQ})$). The medium QC was about midway between the high and low QC concentrations. The high QC was at 75 to 90% of the highest calibration standard. A minimum of three matrix blanks and
15 two water blanks was run with each plate of sample analysis. The plate was vortexed on an Ambi-Hi-Lo incubator (VWR Scientific) for about 5 seconds to mix.

To the plasma samples, calibration standard, QC samples and blanks, 100 μ L of Cutting Probe Working Solution (0.05 μ M
20 template probe complementary to the analyte in 60 mM Na_2HPO_4 , pH 7.4, 0.9 M NaCl, 0.24% Tween-20) was added and the plate was incubated at 37°C for one hour. The 3'-end of the probe is biotinylated and the 5'-end is labeled with digoxigenin (Operon Technologies, Inc.). 150 μ L of this hybridization
25 solution was transferred onto Reacti-Bind™ NeutrAvidin Coated Polystyrene Strip Plates (Clear) (Pierce Chemical Co.) using a multi-channel pipette, and the plate was incubated at 37°C for 30 minutes. After incubation, the plate was refrigerated (4-8°C) for about 10 minutes. The plate was then washed four
30 times with 1XTBS/Tween (25 mM Tris-HCl, pH 7.2, 0.15 M NaCl, 0.1% Tween-20).

To each well was added 300 μ L S1 nuclease solution (50 units/mL of S1 nuclease (Life Technologies) in 30 mM sodium acetate, pH 4.6, 1 mM ZnCl_2 , 5% (v/v) glycerol, and the plate
35 was incubated at room temperature for two hours, then washed.

four times with 1XTBS/Tween. Anti-digoxigenin-alkaline phosphatase (AP) working solution (1:2000 dilution of Anti-digoxigenin-AP, Fab fragments (Boehringer Mannheim). (150 μ L) was added to each well and the plate was incubated at room temperature for 30 minutes. The wells were then washed five times with 1XTBS/Tween. ATTOPHOS Working Solution (60 mL of ATTOPHOS reconstitution solution (JBL Scientific) mixed with 36 mg ATTOPHOS(fluorescent substrate (JBL Scientific)). 150 μ L was added at 10 second increments per row/column. The plate was incubated at 37°C for 10-20 minutes until fluorescence of the most concentrated calibration point reached 18000-23000 at 45 gain. Stop solution (70 μ L of 25% $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ in water (w/v)) was then added at 10 second increments per row/column in the same order as was the ATTOPHOS solution. The plate was read in a fluorescence plate reader (CytoFluor) with the excitation set at 450/50 and the emission at 580/80 at gain of 45 and 42.

Example 2 Selectivity for metabolites

A plate was prepared and concentrations of the following metabolites were measured by the method described in Example 1: N-1 from the 3'-end of ISIS 104838, N-1 from the 3'-end of ISIS 2302 and N-1 from the 5'-end of ISIS 2302. Full-length ISIS 2302 and 104838 were also measured. The results are shown in Fig. 3. All oligonucleotides were detected by the method and produced linear results, although the response for the metabolites was slightly less. Thus, the assay is not selective to metabolites or full length oligonucleotide.

Example 3 Detection of 2'-MOE oligonucleotides

Concentrations of the following 2'-methoxyethyl (2'-MOE) were measured by the method describe in Example 1: ISIS 104838 (SEQ ID NO: 1), ISIS 22023 (SEQ ID NO: 3) and ISIS 113715 (SEQ ID NO:4). Complementary oligonucleotide probes labeled at the 3'-end with digoxigenin and the 5'-end with-

biotin were used to detect each analyte. The results are shown in Fig. 4. All three oligonucleotides showed linearity.

Example 4 Validation of ISIS 22023 in mouse plasma

5 ISIS 22023 was added to mouse plasma to obtain concentrations of 50 pM, 100 pM, 500 pM and 1500 pM. To validate the assay, the protocol described in Example 1 was used to quantitate ISIS 22023 at each of these concentrations. Six replicates of each concentration were analyzed. The results are shown in Table 1. The assay showed good accuracy and precision. The "mean" column indicates the mean concentration of oligonucleotide determined by the assay for the six replicates.

15 **Table 1**

ID	Nominal conc., pM	Mean	SD	Accuracy	%relative SD (RSD)
LOQ	50	52	49	103.4	19.2
Low QC	10	85	15	84.9	17.9
Mid QC	500	571	63	114.2	11.0
20 High QC	1500	1661	158	110.7	9.5

Example 5

Detection of ISIS 22023 after injection in mice
ISIS 22023 (50 mg/kg) was injected subcutaneously into mice and the plasma concentration was determined at various times post-injection by the method described in Example 1. The results are shown in Fig. 5. ISIS 2302 had a very long elimination half-life. The predicted and observed half lives corresponded very well.

30

Example 6 ISIS 104838 Stability studies

Multiple storage vials containing ISIS 104838 at concentrations of 100 pM, 500 pM and 1500 pM were prepared in

monkey plasma and stored at -80°C . To determine freeze-thaw stability, replicates at each concentration were studied after cycles of 1 and 3 freeze-thaws. For determination of short-term room temperature stability, replicates at each concentration were kept at room temperature for 24 hours. The results (Tables 2 and 3; F-T=freeze-thaw) show that ISIS 104838 appeared stable for 24 hours at room temperature in monkey plasma, was stable for 1 day at -80°C , and were stable through freeze-thaw cycles. Results were consistent among freeze-thaw samples and 10-day storage samples.

Table 2

ID	Storage Time	Conc., pM	Accuracy	%RSD
Low QC	24 hr, RT	100	157.9	21.31
Medium QC	24 hr, RT	500	124.6	6.58
High QC	24 hr, RT	1500	96.3	7.12
Low QC	1 F-T	100	109.9	18.90
Medium QC	1 F-T	500	119.1	7.00
High QC	1 F-T	1500	92.9	7.60

Table 3

ID	Storage Time	Conc., pM	Calc. Conc., pM	Accuracy	%RSD
Low QC	3 F-T	100	168	167.6	15.38
Medium QC	3 F-T	500	672	134.3	3.98
High QC	3 F-T	1500	1516	101.0	1.76
Low QC	10 day freezer	100	164	164.2	13.5
Medium QC	10 day freezer	500	715	143.0	22.89
High QC	10-day freezer	1500	1545	103.0	5.01

Example 7 Stability of ISIS 104838 in human plasma

ISIS 104838 was stored at about 20°C and protected from light. The purity of the reference standard was measured by capillary gel electrophoresis and was found to be 99.807%.

5 All samples were analyzed using cutting assay described in Example 1.

Stability of ISIS 104838 in human plasma was studied at nominal values of low (300 pM), medium (750 pM) and high (1500 pM) oligonucleotide concentrations. The actual concentrations
10 determined right after sample preparation were 369, 901 and 1857 pM for low, medium and high, respectively. Room temperature, freeze/thaw and long term freezer storage stability were performed. The samples were stable stored at
15 1 and 24 hr at room temperature (81.3-122.7 of expected concentrations) at all the concentrations examined (Table 4). Following freezer storage at -70°C for 7 days, the samples were also stable (83.9-104.9% of expected concentrations) (Table 5). Following one freeze/thaw cycle, the observed
20 concentration at 369 pM was 52.2% higher than the expected concentration and the observed concentration was in the range of 99.5-120% of expected concentrations at 901 and 1857 pM (Table 6).

Table 4

25	Storage time	Conc. Spiked (pM)	Observed conc. (mean±SD)	%Nominal	%CV
	1 hr	369	300±14	81.3	4.52
		901	775±31	86.0	3.97
		1857	1507±45	81.2	3.01
30	24 hr	369	453±23	122.7	5.15
		901	908±29	100.7	3.22
		1857	1582±50	85.2	3.16

Table 5

	Conc. Spiked (pM)	Observed conc. (pM) (mean±SD)	%Nominal	%CV
	369	387±29	104.9	7.56
5	901	810±125	89.8	15.4
	1857	1558±90	83.9	5.81

Table 6

10	Conc. Spiked (pM)	Observed conc. (pM) (mean±SD)	%Nominal	%CV
	369	561±43	152.2	7.57
	901	1082±77	120.0	7.16
15	1857	1847±44	99.5	2.38

Example 8 Specificity

Control human plasma from ten subjects was analyzed in triplicate for possible endogenous interference. As shown in Table 5, plasma from all subjects had a response less than 50% of the response at the LOQ (100 pM). A linear range of 100 pM (0.1 nM) to 20,000 pM (20 nM) ($r \geq 0.98$) was obtained in human plasma for ISIS 104838. Therefore, no interference was noted from the human plasma.

Table 7

	Subject #	Calc. Conc. (pM) Equivalent to ISIS 104838 (Mean±SD)	%LOQ
	1	4594±1.32	45.94
	2	50.89±0.64	50.89
30	3	47.92±4.65	47.92
	4	44.85±2.81	44.85
	5	46.58±3.61	46.58

6	37.47±5.71	37.47
7	40.65±2.66	40.65
8	42.18±2.12	42.18
9	41.28±2.72	41.28
5 10	37.54±1.38	37.54

Example 9 Calibration curves

Calibration curves (100 to 2000 pM) and 1 to 20 nM) in human plasma were run by two analysts on three different days. Each calibration curve was run in duplicate at concentrations of 100, 200, 500, 1000, 1500, and 2000 pM for the low curve, and 1, 2, 5, 10, 15, 20 nM for the high curve. Each curve was fitted to log/log linear curve without weighting. Representative high and low calibration curves are shown in Figures 6 and 7, respectively. Correlation coefficients for ISIS 104838 were found to be greater than or equal to 0.98 for all calibration curves. Therefore, an acceptable linearity was achieved at concentrations from 100 pM to 20 nM for ISIS 104838 in human plasma.

Example 10 Intra-day accuracy and precision

Six replicate QC samples at four concentrations were used to evaluate intra-day accuracy and precision. The concentrations evaluated were LOQ (100 pM), low (300 pM), medium (750 pM), high (1500 pM) QC and dilution QC (10,000 pM, dilution 1:10) samples performed in human plasma. A 1:10 dilution with blank human plasma was made for the dilution QC sample prior to sample analysis. Intra-day analysis was performed on three different days by two different analysts. Concentrations of ISIS 104838 from the LLOQ, low, medium, high and diluted QC samples were analyzed using the following calibration curve method (Equation 1)

$$\text{Log}_{10}(C_2) = \text{Log}_{10}(\text{Flu}) - \text{intercept/slope} \quad (1)$$

Where C_2 =concentration of the analyte (ISIS 104838), Flu=fluorescence reading of the analyte, intercept and slope were from linear regression of the calibration curve. Accuracy for the QC samples was calculated as the percentage of the calculated concentrations compared to the nominal concentrations for ISIS 104838 (%Actual). Precision was expressed as coefficient of variation (%CV). The results for Days 1 to 3 intra-day accuracy are shown in Tables 8a-8c, respectively.

10

Table 8a

ID	Nominal conc. (pM)	Calc. Conc. (pM) (mean \pm SD)	%Actual	%CV
LOQ	100	91 \pm 14	90.8	15.1
Low QC	300	353 \pm 28	117.7	8.1
Mid QC	750	839 \pm 52	111.8	6.2
High QC	1500	1456 \pm 37	97.1	2.5
Dilution QC	10000	10215 \pm 631	102.2	6.2

15

20

Table 8b

ID	Nominal conc. (pM)	Calc. Conc. (pM) (mean \pm SD)	%Actual	%CV
LOQ	100	82 \pm 11	81.6	13.7
Low QC	300	310 \pm 30	103.4	9.8
Mid QC	750	793 \pm 71	105.7	8.9
High QC	1500	1486 \pm 92	99.1	6.2
Dilution QC	10000	9893 \pm 496	98.9	5.0

25

30

Table 8c

ID	Nominal conc. (pM)	Calc. Conc. (pM) (mean \pm SD)	%Actual	%CV
LOQ	100	93 \pm 20	93.3	21.8
Low QC	300	223 \pm 36	74.4	16.2
Mid QC	750	741 \pm 149	98.8	20.1
High QC	1500	1584 \pm 173	105.6	10.9
Dilution QC	10000	9364 \pm 1758	93.6	18.8

10

Acceptable assay accuracy was achieved for LOQ, low, mid, high and dilution QC (in the range of 90.8-117.7% of nominal spiked concentrations on Day 1, 81.6-105.7% on Day 2, 93.3-105.6% on Day 3) with the exception of the low QC on Day 3, where the %Actual was 74.4%. Therefore, the accuracy acceptance criteria was generally met (75-125% at LOQ and 80-120% at other QC levels). Acceptable intra-day precision (expressed as coefficient of variation, %CV) was less than 21.8% and less than 20.1% for LOQ and QC samples, respectively, which met the acceptance criteria (<25% at LOQ and <20% at other QC levels).

15

20

Example 11 Inter-day precision and accuracy

Inter-day accuracy and precision were calculated from the pooled data of QC using 18 replicates of QC samples each at five different concentrations (100, 300, 750, 1500 and 10,000 pM) performed on three different days by two analysts. Acceptable inter-day assay accuracy was achieved for the quantitation of ISIS 104838 (in the range of 88.6%-105.5% of nominal spiked concentrations over the concentration range studied) (Table 9). Acceptable inter-day assay precision was also obtained (%CV \leq 21.4%), which met the precision acceptance criteria. The dilution QC had an inter-day accuracy at 98.2% with %CV of 11.3%, which met the precision acceptance

25

30

criteria. The inter-day data showed that the method was reproducible in different days and across multiple analysts.

Table 9

5

ID	Nominal conc. (pM)	Observed Conc. (pM) (mean±SD)	%Actual	%CV
LOQ	100	89±16	88.6	17.5
Low QC	300	296±63	98.5	21.4
Mid QC	750	791±102	105.5	12.9
High QC	1500	1509±122	100.6	8.1
Dilution QC	10000	9824±1109	98.2	11.3

10

Example 12 Cross-validation to high range in human plasma

15

In order to determine samples at higher calibration range, a one-day cross-validation at a high range was conducted. In this validation procedure, a six-point calibration standard from 1 nM to 20 nM (at 1, 2, 5, 10, 15 and 20 nM) in duplicate was prepared and analyzed by the cutting assay described in Example 1. Accuracy and precision were assessed with QC samples in six replicates at 2 nM (LLOQ), 5 nM (low QC), 10 nM (medium QC) and 15 nM (high QC) prepared in human plasma. To verify the accuracy and precision of dilution samples, an extra high QC sample (containing 1000 nM of ISIS 104838) in human plasma was prepared in six replicates. A 1:100 dilution with blank human plasma was made for this QC sample prior to sample analysis. For sample preparation of the calibration standards and QC samples, 12.5 µl of standard solution was spiked into 12.5 µl of human plasma and 100 µl of distilled water.

20

25

30

The linear range for the high curve was 1 to 20 nM with $r^2 \geq 0.98$. As shown in Table 10, the accuracy and precision for the LOQ, low, medium and high QC had an %Actual in the range

of 108.3-119.1% with %CV≤10.0%, which met the established accuracy and precision acceptance criteria. The dilution QC had an accuracy of 117.4% with %CV of 6.4%, which also met the accuracy and precision acceptance criteria. In summary, the cross-validation to a high calibration range indicated that the assay was accurate and precise for the quantitation of ISIS 104838 at concentrations between 1 and 20 nM with dilution samples up to 1000 nM (1 μM) in human plasma.

10

Table 10

15

ID	Nominal conc. (nM)	Calc. Conc. (nM) (mean±SD)	%Actual	%CV
LOQ	2	2.27±0.23	113.6	10.0
Low QC	5	5.77±0.27	115.3	4.7
Mid QC	10	11.91±0.70	119.1	5.9
High QC	15	16.24±0.37	108.3	2.3
Dilution QC	1000	1174±75	117.4	6.4

20

In summary, the assay was specific, accurate, precise and sensitive for the quantitation of ISIS 104838 in human plasma. Moreover, the method was reproducible by multiple analysis.

What is Claimed is:

1. A method for detecting or quantitating an oligonucleotide in a bodily fluid or extract, comprising the 5 steps of:

contacting said fluid or extract with a probe complementary to said oligonucleotide, wherein said probe comprises a detectable marker and a binding moiety;

10 placing said fluid or extract in contact with a solid support to which a binding partner of said binding moiety is attached;

contacting said fluid or extract with a single-strand specific nuclease under conditions in which probe which is not hybridized to said oligonucleotide is degraded; and

15 detecting a label associated with said marker, wherein the presence of said label indicates the presence of said oligonucleotide bound to said solid support.

2. The method of Claim 1, wherein said bodily fluid is 20 plasma.

3. The method of Claim 1, wherein said oligonucleotide comprises at least one phosphorothioate linkage.

25 4. The method of Claim 1, wherein said oligonucleotide comprises a modification at the 2' position of at least one sugar moiety.

5. The method of Claim 4, wherein said 2' modification 30 is a 2'-O-methoxyethyl modification.

6. The method of Claim 1, wherein said oligonucleotide comprises at least one modified base.

35 7. The method of Claim 6, wherein said modified base is:

5-methylcytosine.

8. The method of Claim 1, wherein said marker is digoxigenin.

5

9. The method of Claim 1, wherein said label is a colorimetric, radioactive, chemiluminescent, enzymatic or fluorescent label.

10 10. The method of Claim 1, wherein said single-strand specific nuclease is S1 nuclease or mung bean nuclease.

11. The method of Claim 1, wherein said oligonucleotide is exogenously administered.

15

ABSTRACT

A method for quantitating an oligonucleotide in a sample of bodily fluid and/or extract is provided. The method
5 comprises contacting an oligonucleotide with a probe comprising a detectable marker and a binding moiety; placing the fluid or extract in contact with a solid support to which a binding partner of the binding moiety is attached; contacting the fluid or extract with a single-strand specific
10 nuclease to degrade probe which is not hybridized to the oligonucleotide; and detecting a label associated with the marker. The method provides for the detection and/or localization of oligonucleotides, including administered modified oligonucleotides, for therapeutic and/or
15 pharmacokinetic purposes.

FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6





FIGURE 7



Docket No.
ISPH-0500

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

NUCLEASE-BASED METHOD FOR DETECTING AND QUANTITATING OLIGONUCLEOTIDES

the specification of which

(check one)

☒ is attached hereto.

☐ was filed on _____ as United States Application No. or PCT International Application Number _____ and was amended on _____ (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)			Priority Not Claimed
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/>
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/>
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/>

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*

Jane Massey Licata, Reg. No. 32,257

Kathleen A. Tyrrell, Reg. No. 38,350

Laura Plunkett, Reg. No. 45,015

of the firm

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, NJ 08053

Herb Boswell, Reg. No. 27,311

Laurel Spear Bernstein, Reg. No. 37,280

Robert S. Andrews, Reg. No. 44,508

April Logan, Reg. No. 33,950

Neil S. Bartfeld, Reg. No. 39,901

of the firm

Isis Pharmaceuticals, Inc.
Carlsbad Research Center
2292 Faraday Avenue

Send Correspondence to: Jane Massey Licata
Licata & Tyrrell P.C.
66 E. Main Street
Marlton, NJ 08053

Direct Telephone Calls to: *(name and telephone number)*
Jane Massey Licata Tel: 856-810-1515

Full name of sole or first inventor Zhengrong Y. Yu	
Sole or first inventor's signature	Date
Residence Carlsbad, CA	
Citizenship China	
Post Office Address 7808 Calle Lomas	
Carlsbad, CA	

Full name of second inventor, if any Brenda F. Baker	
Second inventor's signature	Date
Residence Carlsbad, CA	
Citizenship US	
Post Office Address 2147 Avenida Toronja	
Carlsbad, CA	

Full name of third inventor, if any John Wu	
Third inventor's signature	Date
Residence Carlsbad, CA	
Citizenship USA	
Post Office Address 7831 Calle Pina Bete	
Carlsbad, CA	

Full name of fourth inventor, if any	
Fourth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

Full name of fifth inventor, if any	
Fifth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

Full name of sixth inventor, if any	
Sixth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

SEQUENCE LISTING

<110> Zhengrong Yu
Brenda F. Baker
John Wu

<120> Nuclease-Based Method for Detecting and Quantitating
Oligonucleotides

<130> ISPH-0500

<160> 4

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> antisense oligonucleotide

<400> 1

gctgattaga gagaggtccc

20

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> antisense oligonucleotide

<400> 2

gccaagctg gcatccgtca

20

<210> 3

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> antisense oligonucleotide

<400> 3

tccagcactt tcttttccgg

20

<210> 4

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> antisense oligonucleotide

<400> 4

gctccttcca ctgatactgc

20